Determinants of HIV-1 broadly neutralizing antibody induction

[1]  Camille Roth,et al.  Natural Scales in Geographical Patterns , 2017, Scientific Reports.

[2]  Nico Pfeifer,et al.  HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption , 2016, Nature.

[3]  Ben Murrell,et al.  Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort , 2016, PLoS pathogens.

[4]  J. Mascola,et al.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.

[5]  Lynn Morris,et al.  Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies , 2015, Nature Medicine.

[6]  Alan S. Perelson,et al.  Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising , 2015, Proceedings of the National Academy of Sciences.

[7]  L. Held,et al.  Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. , 2015, The Journal of infectious diseases.

[8]  R. McClelland,et al.  The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection , 2015, PLoS pathogens.

[9]  Hyejin Yoon,et al.  CATNAP: a tool to compile, analyze and tally neutralizing antibody panels , 2015, Nucleic Acids Res..

[10]  John R Mascola,et al.  Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.

[11]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[12]  L. Morris,et al.  Virological features associated with the development of broadly neutralizing antibodies to HIV-1. , 2015, Trends in microbiology.

[13]  I. Wilson,et al.  Insights into the trimeric HIV-1 envelope glycoprotein structure. , 2015, Trends in biochemical sciences.

[14]  Jerome H. Kim,et al.  Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies , 2014, Journal of Virology.

[15]  J. Overbaugh,et al.  Early development of broad neutralizing antibodies in HIV-1 infected infants , 2014, Nature Medicine.

[16]  L. Morris,et al.  Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection , 2014, Current opinion in HIV and AIDS.

[17]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[18]  B. Korber,et al.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.

[19]  B. Haynes,et al.  Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies , 2013, Vaccines.

[20]  Alessandro Sette,et al.  Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. , 2013, Immunity.

[21]  L. Morris,et al.  Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.

[22]  Florian Klein,et al.  Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.

[23]  L. Morris,et al.  Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[24]  Young Do Kwon,et al.  Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains , 2013, Journal of Virology.

[25]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[26]  Tongqing Zhou,et al.  Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization , 2013, Science.

[27]  Tongqing Zhou,et al.  Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.

[28]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[29]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[30]  Adam Godzik,et al.  A Blueprint for HIV Vaccine Discovery. , 2012, Cell host & microbe.

[31]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[32]  S. Aris-Brosou,et al.  Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. , 2012, The Journal of infectious diseases.

[33]  K. Metzner,et al.  Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  H. Schuitemaker,et al.  Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity , 2011, Journal of Virology.

[35]  H. Günthard,et al.  The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. , 2011, The Journal of infectious diseases.

[36]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[37]  Huldrych F. Günthard,et al.  Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies , 2011, The Journal of experimental medicine.

[38]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[39]  Beda Joos,et al.  Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.

[41]  Amalio Telenti,et al.  Cohort profile: the Swiss HIV Cohort study. , 2010, International journal of epidemiology.

[42]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.

[43]  H. Günthard,et al.  HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men , 2010, AIDS.

[44]  Matthias Cavassini,et al.  Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. , 2010, The Journal of infectious diseases.

[45]  Richard T. Wyatt,et al.  Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.

[46]  J. Baeten,et al.  Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression , 2009, Journal of Virology.

[47]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[48]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[49]  Patrick Taffé,et al.  A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort , 2008, Statistics in medicine.

[50]  Lynn Morris,et al.  Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.

[51]  Douglas D. Richman,et al.  Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.

[52]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[53]  S. Self,et al.  Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. , 2004, The Journal of infectious diseases.

[54]  M. Hersberger,et al.  Deliberate removal of T cell help improves virus-neutralizing antibody production , 2004, Nature Immunology.

[55]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[56]  J. Margolick,et al.  Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[57]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[58]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[59]  William M. Rand,et al.  Objective Criteria for the Evaluation of Clustering Methods , 1971 .